TITLE

TARO PHARMACEUTICALS ACQUIRES TIAMOL FOR U.S./CANADA

PUB. DATE
September 2000
SOURCE
Worldwide Biotech;Sep2000, Vol. 12. Issue 9, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports the market approval received by Tiamol, a dermatologic drug frok Taro Pharmaceutical Industries Inc., in the United States and Canada.
ACCESSION #
3533627

 

Related Articles

  • FDA APPROVES TARO'S ANDA FOR KETOCONAZOLE CREAM.  // Biotech Business;Feb2003, Vol. 16 Issue 2, p4 

    Reports on the approval by the U.S. Food and Drug Administration of Taro Pharmaceutical Industries' abbreviated new drug application for Ketoconazole Cream, as of February 2003.

  • Taro 2011 Annual Report on Form 20-F Available.  // Biomedical Market Newsletter;5/12/2012, Vol. 21, p1 

    The article offers information on the release of Taro Pharmaceutical Industries Ltd.'s financial report for the fiscal year ended Dec 31, 2011 on Form 20-F which is available on company's website.

  • CHAIN PHARMACY. Frederick, James; West, Diane // Drug Store News;2/18/2002, Vol. 24 Issue 2, p20 

    Presents an update on drug chains in the U.S. as of February 2002. Anniversary celebration of Taro Pharmaceuticals in the NASDAQ listing; Approval of a plan to create a formulary or preferred drug list.

  • Change to Taro's Board of Directors.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p625 

    The article announces the resignation of Ilan Leviteh as a member of the Board of Directors of Taro Pharmaceutical Industries Ltd.

  • Co Profile for Taro Pharmaceutical Industries Ltd.  // Biomedical Market Newsletter;4/1/2012, Vol. 21, p1 

    A company profile for Taro Pharmaceutical Industries Ltd. is presented.

  • Kal Sundaram Appointed to Taro's Board of Directors as Chairman.  // Biomedical Market Newsletter;4/21/2012, Vol. 21, p1 

    The article announces the appointment of Kalyanasundaram Subramanian as chairman of the board of directors at Taro Pharmaceutical Industries Ltd.

  • Taro to Announce Financial Results for the Quarter Ended June 30 2012.  // Biomedical Market Newsletter;8/7/2012, Vol. 21, p1 

    The article informs that the quarter financial results that ended on June 30, 2012 will be announced by Taro Pharmaceutical Industries Ltd.

  • FDA APPROVES TARO'S ANDA FOR DIFLORASONE DIACETATE CREAM.  // Worldwide Biotech;Jun2000, Vol. 12 Issue 6, p2 

    Reports that Taro Pharmaceuticals Inc. has received notification from the United States Food and Drug Administration approving its Abbreviated New Drug Application for Diflorasone Diacetate Cream.

  • FDA approves ANDA for Taro's Ketoconazole.  // Drug Store News;7/19/99, Vol. 21 Issue 11, pCP6 

    Reports the approval of the United States Food and Drug Administration for Taro Pharmaceutical Industries' to market the anti-fungal drug Ketoconazole Tablets USP, 200 milligrams. Brief information on the drug.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics